Why Melanoma Spreads More in Middle Age — A Mouse Study Points to the Immune System - brieflycurious.com

Why Melanoma Spreads More in Middle Age — A Mouse Study Points to the Immune System

Daniel Novak

June 1, 2026

Follow us on Google News

Melanoma spreads more aggressively in middle age than late life. Fox Chase researchers link the pattern to γδ T cells and PROS1, and warn young-mouse studies can mislead.

Photo by Olga Thelavart on Unsplash

With cancer, the simple expectation is often: the older you are, the higher the risk. Melanoma doesn’t fit that pattern neatly. Clinical data show melanoma rates climb into later life—especially between about 65 and 79 years old—and then decline after about age 79. That doesn’t mean people over 80 are protected; rather, it suggests tumors may act differently at different stages of aging.

That nuance also exposes a gap in cancer research. Many lab studies still use young mice, animals whose biology is closer to that of a young adult than to the older patients who most commonly get melanoma . As a Fox Chase Cancer Center news release notes, fewer than 10 percent of mouse studies use aged animals even though melanoma is mainly a disease of older adults. A therapy that looks effective in a young, resilient immune system can behave very differently in an older body.

Metastasis Peaked in Middle-Aged, Not Old, Mice

Researchers at Fox Chase Cancer Center looked beyond primary tumor growth to ask where melanoma cells take hold after they leave the original site. They injected melanoma cells into mice of different ages and then examined organs where metastases commonly appear, especially the lungs and liver.

The results didn’t follow a straight line. Melanoma spread was lowest in young mice, highest in middle-aged mice, and lower again in very old mice . That pattern echoes clinical observations: incidence increases with age, peaks, and then falls in the very old. It doesn’t mean older people are safe, but it does imply age changes how tumors and the body interact.

Photo by Joshua J. Cotten on Unsplash<br>The trail led to a group of immune cells called gamma delta (γδ) T cells. Think of these cells as a rapid-response patrol in tissues: they act quickly when cells start acting abnormally instead of waiting for a full-blown immune reaction. Young and very old mice had more of these protective γδ T cells near likely metastatic sites, while middle-aged mice had fewer—exactly where metastasis was most aggressive.

When researchers experimentally removed γδ T cells, melanoma cells established more readily in lungs and liver. That’s important because a tumor’s danger isn’t just its primary size; it’s the cancer’s ability to seed new tumors elsewhere. In this model, γδ T cells seemed to act as a brake on metastasis, and melanoma found a way around that brake in middle age.

The Tumor Appears to Undermine Its Own Restraints

The strongest clue the team found involved a molecule called PROS1. The study reports that melanoma cells released PROS1 when they reactivated in middle-aged mice, and that release helped the cancer spread more effectively . In other words, the tumor wasn’t just waiting for the immune system to weaken with age; it was actively shaping conditions that made new metastatic sites easier to establish.

Photo by National Cancer Institute on Unsplash<br>PROS1 functions as a signaling molecule that alters the tumor microenvironment. The data indicate it supported cancer cell proliferation and correlated with fewer γδ T cells at metastatic locations. In experiments where melanoma cells were engineered to overproduce PROS1 and then injected into young mice, the cancer spread more aggressively to lungs and liver, and the protective immune cells were reduced at those sites.

This is the study’s central takeaway: melanoma may not use the same strategy at every age . Instead, it may capitalize on age-related shifts in immune defenses. In middle-aged mice, that meant reduced γδ T-cell protection paired with elevated PROS1 activity. In very old mice, the immune landscape looked different—and metastasis was less aggressive—helping explain why a simple “older is worse” model doesn’t always apply.

Why Young Mice Can Make Drugs Look Better Than They Are

The implications go beyond melanoma. Testing a drug in a young mouse means testing in a body with a robust, relatively intact immune system. But many cancer patients are decades older, with different immune profiles, tissue environments, and tolerances for side effects . If a tumor spreads through one immune weakness in an older body but via a different route in a young model, preclinical studies can miss the real clinical problem.

Mitchell Fane, PhD, the study’s lead investigator at Fox Chase, highlighted that concern: “The vast majority of studies are done in these very young mice.” The choice is practical—young mice are cheaper and faster to work with—yet that convenience can create a blind spot. Results that look clean in...